Tue. 14 Jun 2022, 8:14am ET Benzinga Biotech, General
  • reSET-O® is the only FDA-authorized prescription digital therapeutic (PDT) for the treatment of opioid use disorder (OUD)
  • Results support the real-world value of reSET-O, demonstrating durable treatment outcomes and reductions in healthcare resource utilization
  • 12-month analysis builds on prior publications of population-level improvements in health care resource utilization for reSET-O at 6 and 9 months, as data demonstrated >$3,800 per patient cost savings for the Medicaid population1

BOSTON--(BUSINESS WIRE)-- Pear Therapeutics, Inc. (NASDAQ:PEAR), the leader in developing and commercializing software-based medicines, called prescription digital therapeutics (PDTs), today announced a manuscript accepted for publication and available via pre-print of a real-world study demonstrating reduced health care resource utilization and associated costs for reSET-O®, the only FDA-authorized PDT for the treatment of opioid use disorder (OUD).

Results from a 12-month real-world data study of reSET-O showed a reduction in healthcare utilization, particularly inpatient (IP) stays (which also include ICU stays and readmissions) and emergency department (ED) visits, contributing to a net cost reduction of $3,832 per patient for the Medicaid population, and an increase in buprenorphine adherence in patients with OUD treated with reSET-O compared to controls, based on a linear model of the medication possession ratio.

This health economic study was accepted for publication and made available via pre-print by the international peer-reviewed journal Advances in Therapy.1

“The data show our health economic outcomes for reSET-O now go out to 12 months, demonstrating durability of the clinical effect for opioid use disorder patients, which is an often difficult to treat patient group as shown in part by the record number of overdose deaths over the last year,” said Yuri Maricich, M.D., Chief Medical Officer and Head of Development at Pear Therapeutics. “To overcome the opioid crisis, we must increase access to treatment options that may improve outcomes. The results of this analysis demonstrated that patients who were treated with reSET-O showed lower incidence of inpatient stays and emergency department visits, compared to control patients.”

The study used claims data to evaluate 901 adult patients who were prescribed and treated with reSET-O compared to 978 controls. Compared to the control group, the 12-month period post-initiation of reSET-O showed reductions in:

  • IP stays (28% reduction; IRR: 0.72; 95% CI: 0.55-0.96; P=0.026) which included a 30% reduction in ICU stays and a 56% reduction in readmissions).
  • ED visits (7% reduction; IRR: 0.93; 95% CI: 0.79-1.09; P=0.386).
  • Per-patient costs across all-payer mix by an estimated $2,791 and per-patient costs for the Medicaid population, specifically by an estimated $3,832 reduction.1

Results also showed that among those patients on buprenorphine therapy, adherence significantly increased among those treated with reSET-O vs controls, based on a linear model of the medication possession ratio, despite both groups having similar buprenorphine adherence at baseline.1 Additionally, this study adds to a larger body of evidence for reSET-O that now spans 6, 9 and 12 months both pre-post and vs. controls.

The full paper is available online by clicking here.

reSET-O has been evaluated in randomized controlled trials, in real-world clinical, and real-world health economic studies.1-13